Exit strategies of pharmaceutical multinational companies from Portugal and the successful implementation of new Portuguese companies

Abstract

In 2001 and 2004, two multinational companies (MNC) of the pharmaceutical industry, respectively Bayer and Janssen, left its manufacture operations in Portugal. From its exit, other two Portuguese small and medium enterprises (SME) were born: Bluepharma and Lusomedicamenta. These companies have been highly successful due to the representativeness of exports, contract-manufacturing and generic production. This report intents to study the exit of the MNC and the implementation of the Portuguese SMEs.